Патогенетична терапія цервікальної інтраепітеліальної неоплазії ІІ–ІІІ ступеня важкості

Л. І. Воробйова; В. В. Дунаєвська; А. М. Кошмеринська

doi:10.18370/2309-4117.2015.24.74-77

Authors

Л. І. Воробйова National Cancer Institute (Kyiv), Ukraine
В. В. Дунаєвська National Cancer Institute, Kyiv, Ukraine
А. М. Кошмеринська Zhytomyr Regional Oncology Center, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2015.24.74-77

Keywords:

human papillomavirus, cervical cancer, antiviral drugs, indole-3-carbinol, cervical intraepithelial neoplasia, Epigalin®

Abstract

The secondary prevention of cervical cancer include detection and treatment of preinvasive forms of the disease, which includes cervical intraepithelial neoplasia and atypical cervix leucoplachia. 98% cases of this pathology are associated with human papillomavirus. Traditional surgical methods of treatment of cervical intraepithelial neoplasia do not always lead to the elimination of the virus, that cannot completely exclude the possibility of recurrence. The article shows the literature data and own observations about the possibility of drug therapy in complex therapy of neoplasia. It is accentuated that the using of antiviral and immune drugs, biologically active complexes consisting of medical actions can achieve higher efficiency in comparison with surgical methods.

Author Biographies

Л. І. Воробйова, National Cancer Institute (Kyiv)

MD, head of the Scientific and Research Department of Gynecologic Oncology;

Chief oncogynecologist of the Ministry of Health of Ukraine

В. В. Дунаєвська, National Cancer Institute, Kyiv

PhD, oncogynecologist

А. М. Кошмеринська, Zhytomyr Regional Oncology Center

Oncogynecologist

References

Bebneva, T.N. “Some clinical aspects of HPV infection.” Gynecology, 1 (Vol. 9) (2007): 20–24.
Prilepskaya, V.N., Rogovskaya, S.I., Kondrikov, N.I., Sukhyh, G.T. Human papillomavirus infection: diagnosis, treatment and prevention. Moscow. MEDpress-inform (2007): 32 p.
Rogovskaya, S.I., Prilepskaya, V.N. “New technologies in cervical cancer prevention.” Gynecology, 1 (Vol. 10) (2008): 4–7.
Rogovskaya, S.I. HPV infection in women, and pathology of the cervix: To help the practitioner physician. 2nd ed. Moscow. GEOTAR -Media (2008): 192 p.
Sukhyh, G.T., Prilepskaya, V.N. New screening technology in cervical cancer prevention // Materials of the International scientific and practical conference “Prevention of Cervical Cancer: A look into the future.” Moscow (2008): 110–111.
Yakovleva, V.A. The surface structure of cervical epithelial cells infected with the human papilloma virus: dissertation on the degree of candidate of biological sciences. Moscow (2009): 108 p.
Sperling, N.V., Vengerovsky, A.I., Persidskaya, O.A., Sperling, I.A. “Experience of the indinol use for recurrent genital HPV infection.” Clinical Dermatology and Venereology, 2 (2009): 32–36.
Ashrafyan, L.A., Kiselev, V.I. Tumors of the reproductive organs (etiology and pathogenesis). Moscow (2007): 208 p.
Kiselev, V.I., Muyzhnek, E.L. Molecular mechanisms of the cervical dysplasia development: new knowledge – new opportunities. Moscow (2012).
C hung, S.H., Wiedmeyer, K., Shai, A., Korach, K.S., Lambert, P.F. “Requirement for estrogen receptor α in a mouse model for human papillomavirus-associated cervical cancer.” Cancer Res, 68(23) (2008): 9928–9934.
D e Vuyst, H., Clifford, G., Li, N., Franceschi, S. “HPV infection in Europe.” Eur J Cancer, 45(15) (2009): 2632–2633.
Fang, M.Z., Wang, Y., Ai, N., Hou, Z., Sun, Y., Lu H., et al. “Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines.” Cancer Res, 63(22) (2003): 7563–7570.
Gorodetskaya, S.B., Sveshnikov, P.G., Budarina, S.O., et al. “The value of the study of the level expression of HPV-16 and -18 types E7 oncoprotein in cervical material in the diagnosis of neoplastic formations of the cervix.” Molecular Medicine, 5(2010).
Podistov, Y.I., Laktionov, K.P., Petrovichev, N.N., Bryuzgin, V.V. Epithelial dysplasia of the cervix (diagnosis and treatment). Moscow (2006): 133 p.
Jabbar, S.F., Abrams, L., Glick, A., Lambert, P.F. “Persistent of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papilloma virus type 16 E7 oncogene.” Cancer Res, 69(10) (2009): 4407–4414.
He, H.J., Pan, L.Y. Huang, H.F., Lang, J.H. “Clinical analysis of the effect of cervical conization in fertility and pregnancy outcome.” Zhonghua Fu Chan Ke Za Zhi, 42(8) (2007): 515–521.
Qi, M., Anderson, A.E., Chen, D.Z., Sun, S., Auborn, K.J. “Indole-3-carbinol prevents PTEN loss in cervical cancer in vivo.” Mol Med, 11(2005): 59–63.
Sokolovsky, E.V., Ignatovsky, A.B. “Immunomodulatory therapy of human papillomavirus infection.” Questions of Gynecology, Obstetrics and Perinatology, 4 (Vol. 4) (2005): 27–30.
Frolova, I.I., Babichenko, I.I., Mestergazi, G.M. Cervical intraepithelial neoplasia and cervical dyskeratosis. Moscow. Dynasty (2004): 88 p.
Shipitsyna, E.B., Zolotoverkhaya, E.A., Yushmanova, E.S., Savicheva, A.M. “Diagnosis of HPV infection in cervical cancer screening.” Journal of Obstetrics and Gynecological Diseases, 56(2007): 72–75.
Teletaeva, G.M. “Cytokines and antitumor immunity.” Practical Oncology, 4 (Vol. 8) (2007): 211–218.
Bottley, G., Watherston, O.G., Hiew, Y.L., et al. “High-risk human papillomavirus E7 expression reduces cellsurface MHC class I molecules and increases susceptibility to natural killer cells.” Oncogene, 12 (Vol. 27) (2008): 1794–1799.
Brinton, L.A., Reeves, W.C., Brenes, M.M., et al. “Prity as a risk factor for cervical cancer.” Am J Epidemiol, 130(1999): 486–496.
Broom, J.K., Lew, A.M., Azukizawa, H., et al. “Antigen-specific CD4 cells assist CD8 T-effector cells in eliminating keratinocytes.” J Invest Dermatol, 6 (Vol. 130) (2010): 1581–1589.
Brown, D.R., Legge, D., Qadadri, B. “Distribution of human papillomavirus types in cervicovaginal washings from women evaluated in a sexually transmitted diseases clinic.” Sex Transm Dis, 29(2002): 763–768.
Brown, D.R., Shew, M.L., Qadadri, B., et al. “A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women.” J Infect Dis, 191(2005): 182.
Bruni, L., M. Diaz, M., Castellsague, X. “Cervical human papillomavirus prevalence in 5 continents: metaanalysis of 1 million women with normal cytological findings.” J Infect Dis, 12 (Vol. 202) (2010): 1789–1799.
C ampo, M.S., Graham, S.V., Cortese, M.S., et al. “HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells.” Virology, 1 (Vol. 407) (2010): 137–142.
C astellsague, X., Bosch, F.X., Munoz, N. “Environmental co-factors in HPV carcinogenesis.” Virus Res, 89(2002): 191–199.
C astle, P.E., Schiffman, M., Gravitt, P.E. “Comparisons of HPV DNA detection by MY09/11 PCR methods.” J Med Virol, 3 (Vol. 68) (2002): 417–423.
C astle, P.E., Schiffman, M., Wheeler, C.M., et. al. “Human, papillomavirus genotypes in cervical intraepithelial neoplasia grade 3.” Cancer Epidemiol Biomarkers Prev, 7 (Vol. 19) (2010): 1675–1681.